Payment overview · 2025
General Payments
$1,020.55
40 reported records · 13 companies
Healthcare provider profile · identity verified
George L Restea, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KEYSTONE HEIGHTS, FL · NPI 1881664951
Verified facts
What the public records show
CMS Open Payments records show George L Restea, MD received $1,020.55 in general payments during 2025 across 40 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $326.46 | 32.0% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $225.83 | 22.1% | 7 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $191.14 | 18.7% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.81 | 6.7% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $52.46 | 5.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.19 | 2.2% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $21.82 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.66 | 2.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.15 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.58 | 1.8% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $18.18 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.52 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.75 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,020.55 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $326.46 | 13 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $191.14 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $171.58 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $146.64 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.81 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.25 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $52.46 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 532 | 65 |
| Gabapentin | Gabapentin | 435 | 68 |
| Oxycodone Hcl | Oxycodone Hcl | 335 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 333 | 86 |
| Omeprazole | Omeprazole | 295 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 265 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 241 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 192 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 176 | 44 |
| Clonazepam | Clonazepam | 172 | 23 |
| Pregabalin | Pregabalin | 160 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 24 |
| Lisinopril | Lisinopril | 154 | 46 |
| Lorazepam | Lorazepam | 145 | 21 |
| Metformin Hcl | Metformin Hcl | 141 | 37 |
| Azithromycin | Azithromycin | 139 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 21 |
| Buprenorphine Hcl | Buprenorphine Hcl | 132 | 17 |
| Trazodone Hcl | Trazodone Hcl | 132 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 125 | 14 |
| Furosemide | Furosemide | 123 | 39 |
| Ondansetron Odt | Ondansetron | 121 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 26 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 119 | 12 |
| Diazepam | Diazepam | 116 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 40 |
| Methylprednisolone | Methylprednisolone | 114 | 75 |
| Meloxicam | Meloxicam | 113 | 23 |
| Montelukast Sodium | Montelukast Sodium | 110 | 32 |
| Losartan Potassium | Losartan Potassium | 95 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 28 |
| Ibuprofen | Ibuprofen | 92 | 21 |
| Clonidine Hcl | Clonidine Hcl | 90 | 18 |
| Tramadol Hcl | Tramadol Hcl | 86 | 17 |
| Promethazine Hcl | Promethazine Hcl | 82 | suppressed |
| Carvedilol | Carvedilol | 81 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 78 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 23 |
| Topiramate | Topiramate | 75 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 73 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 11 |
| Prednisone | Prednisone | 70 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 23 |
| Mounjaro | Tirzepatide | 66 | 13 |
| Potassium Chloride | Potassium Chloride | 66 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 38 |
| Buspirone Hcl | Buspirone Hcl | 62 | 15 |
| Glipizide | Glipizide | 61 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 16 |
| Baclofen | Baclofen | 59 | 14 |
| Eliquis | Apixaban | 59 | 11 |
| Mirtazapine | Mirtazapine | 57 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 15 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 16 |
| Methocarbamol | Methocarbamol | 47 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 47 | 11 |
| Atenolol | Atenolol | 45 | 13 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Fluconazole | Fluconazole | 45 | 20 |
| Simvastatin | Simvastatin | 44 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 43 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 29 |
| Famotidine | Famotidine | 41 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 12 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | 11 |
| Carisoprodol | Carisoprodol | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 14 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 38 | suppressed |
| Cefadroxil | Cefadroxil | 37 | 12 |
| Nystatin | Nystatin | 37 | 19 |
| Belsomra | Suvorexant | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Vilazodone Hcl | Vilazodone Hcl | 36 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 11 |
| Methadone Hcl | Methadone Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 21 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 11 |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 12 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 11 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,020.55 · 40 records | Bayer Healthcare Pharmaceuticals Inc. | CAPLYTA, Cologuard Collection Kit, FARXIGA, Hillrom - Vest System Model 105 Home Care, JOURNAVX, Kerendia, MOUNJARO, Ozempic, QULIPTA, Quviviq, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error